PR Newswire
CAMBRIDGE, Mass., May 8, 2018
CAMBRIDGE, Mass., May 8, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced its first quarter 2018 financial results for the period ended March 31, 2018.
"At Merrimack, we set out to design targeted solutions with pharmacological properties to match our team's understanding of cancer pathways and drug metabolism. We have been focused on executing this strategy as we advance the ten wholly-owned programs across our clinical and preclinical pipeline, each addressing biomarker-defined cancers," said Richard Peters, M.D., Ph.D., President and Chief Executive Officer. "We look forward to our three upcoming clinical readouts: randomized Phase 2 data for istiratumab (MM-141) in pancreatic cancer and seribantumab (MM-121) in non-small cell lung cancer and Phase 1 data for MM-310 in solid tumors."
First Quarter and Recent Highlights
Key events from the first quarter and more recently include:
Upcoming Milestones
Merrimack anticipates the following upcoming clinical milestones:
First Quarter 2018 Financial Results
The following summarizes Merrimack's financial results for the three months ended March 31, 2018:
Financial Outlook
Merrimack continues to believe that its cash and cash equivalents and marketable securities of $76.3 million as of March 31, 2018 and certain potential net milestone payments anticipated from Shire will be sufficient to fund its planned operations into the second half of 2019.
Conference Call and Webcast
Merrimack will host a live conference call and webcast today, Tuesday, May 8, 2018 at 8:30 am ET, to provide an update on its operational progress and a summary of these financial results.
Investors and the general public are invited to listen to the call by dialing (877) 564-1301 (domestic) or (224) 357-2394 (international) five minutes prior to the start of the call and providing the passcode 1596995. A listen-only webcast of the call can be accessed in the Investors section of Merrimack's website, investors.merrimack.com, and a replay of the call will be archived there for six weeks following the call.
About Merrimack
Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. Its mission is to transform cancer care through the smart design and development of targeted solutions based on a deep understanding of cancer pathways and biological markers. All of Merrimack's development programs, including four clinical studies and six candidates in preclinical development, fit into its strategy of 1) understanding the biological problems it is trying to solve, 2) designing specific solutions and 3) developing those solutions for biomarker-selected patients. This three-pronged strategy seeks to ensure optimal patient outcomes. For more information, please visit Merrimack's website at www.merrimack.com.
Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include any statements about Merrimack's strategy, future operations, future financial position, future revenues and future expectations and plans and prospects for Merrimack, and any other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue" and similar expressions. In this press release, Merrimack's forward-looking statements include, among others, statements about the timing of availability of clinical trial data, the anticipated achievement of milestones and the availability of funding sufficient to fund Merrimack's operations. Such forward-looking statements involve substantial risks and uncertainties that could cause Merrimack's clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the availability of data from ongoing clinical trials, expectations for regulatory approvals, development progress of Merrimack's companion diagnostics, availability of funding sufficient for Merrimack's foreseeable and unforeseeable operating expenses and capital expenditure requirements, and other matters that could affect the availability or commercial potential of Merrimack's product candidates or companion diagnostics. Merrimack undertakes no obligation to update or revise any forward-looking statements. Forward-looking statements should not be relied upon as representing Merrimack's views as of any date subsequent to the date hereof. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Merrimack's business in general, see the "Risk Factors" section of Merrimack's Annual Report on Form 10-K filed with the SEC on March 12, 2018 and the other reports Merrimack files with the SEC.
Merrimack Pharmaceuticals, Inc. (unaudited) | |||||
| | ||||
| Three Months Ended March 31, | ||||
(in thousands, except per share amounts) | 2018 | | 2017 | ||
Operating expenses: | | | | | |
Research and development expenses | $ | 13,106 | | $ | 21,605 |
General and administrative expenses | | 4,270 | | | 5,634 |
Total operating expenses | | 17,376 | | | 27,239 |
Loss from continuing operations | | (17,376) | | | (27,239) |
Other income and expenses: | | | | | |
Interest income | | 275 | | | 14 |
Interest expense | | — | | | (1,979) |
Other income (expense), net | | (681) | | | (2) |
Total other income and expenses | | (406) | | | (1,967) |
Net loss from continuing operations | | (17,782) | | | (29,206) |
Discontinued operations: | | | | | |
Loss from discontinued operations, net of tax | | — | | | (947) |
| | | | | |
Net loss | | (17,782) | | | (30,153) |
Net loss attributable to non-controlling interest | | — | | | (467) |
Net loss attributable to Merrimack Pharmaceuticals, Inc. | $ | (17,782) | | $ | (29,686) |
| | | | | |
Other comprehensive loss: | | | | | |
Unrealized loss on marketable securities | | (12) | | | — |
Other comprehensive loss | | (12) | | | — |
Comprehensive loss | $ | (17,794) | | $ | (29,686) |
| | | | | |
Amounts attributable to Merrimack Pharmaceuticals, Inc.: | | | | | |
Net loss from continuing operations | $ | (17,782) | | $ | (28,739) |
Loss from discontinued operations, net of tax | | — | | | (947) |
Loss attributable to Merrimack Pharmaceuticals, Inc. | $ | (17,782) | | $ | (29,686) |
Basic and dilutive net loss per common share | | | | | |
Net loss from continuing operations Werbung Mehr Nachrichten zur Merrimack Pharmaceuticals Inc Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1 Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News |